Safety considerations for use of bone-targeted agents in patients with cancer

Seminars in Oncology

Volumn 37, Issue SUPPL., 2010, Pages

  Mortimer, Joanne E ^a   Pal, Sumanta Kumar ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE DISEASE; BONE NECROSIS; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ELECTROLYTE DISTURBANCE; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LONG TERM CARE; MYALGIA; NEPHROTOXICITY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; RIGOR;

EID: 77955450684     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.06.006     Document Type: Article

References (51)

1. M.J. Lage, B.L. Barber, D.J. Harrison, and S. Jun The cost of treating skeletal-related events in patients with prostate cancer Am J Manag Care 14 2008 317 322
2. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
3. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593
4. M. Aapro, P.A. Abrahamsson, and J.J. Body, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 2008 420 432
5. D. Henry, R. von Moos, and S. Vadhan-Raj A, et al. double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [abstract] Eur J Cancer Suppl (Meeting Abstracts) 2009 7:2LBA
6. A. Stopeck, J.J. Body, and Y. Fujiwara, et al. Denosumab versus zoledronic acid for the treatments of breast cancer patients with bone metastases: results of a randomized phase 3 study [abstract] Eur J Cancer Suppl (Meeting Abstracts) 2009 7:20LBA
7. B.E. Hillner, J.N. Ingle, and J.R. Berenson, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer J Clin Oncol 18 2000 1378 1391
8. F. Saad, and C.C. Schulman Role of bisphosphonates in prostate cancer Eur Urol 45 2004 26 34
9. United States Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs. Published August 13, 2009. Available from: www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisorycommittee/ UCM176605.pdf.
10. M. Gnant, P. Dubsky, and F. Fitzal, et al. Bisphosphonates as adjuvant therapy for breast cancer Curr Breast Cancer Rep 1 2009 54 63
11. M.F. Gnant, B. Mlineritsch, and G. Luschin-Ebengreuth, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 25 2007 820 828
12. Rothstein A. Denosumab safety FDA analysis. Published August 13, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ UCM187083.pdf.
13. S.L. Ruggiero, and B. Mehrotra Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management Annu Rev Med 60 2009 85 96
14. T. Tanvetyanon, and P.J. Stiff Management of the adverse effects associated with intravenous bisphosphonates Ann Oncol 17 2006 897 907
15. L.S. Rosen, D. Gordon, and M. Kaminski, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 2001 377 387
16. L.S. Rosen, D. Gordon, and M. Kaminski, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
17. F. Saad, D.M. Gleason, and R. Murray, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
18. F. Saad, D.M. Gleason, and R. Murray, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
19. G. Dicuonzo, B. Vincenzi, and D. Santini, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 J Interferon Cytokine Res 23 2003 649 654
20. P.P. Major, and R.E. Coleman Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program Semin Oncol 28 2001 17 24
21. K.D. Crew, E. Shane, S. Cremers, D.J. McMahon, D. Irani, and D.L. Hershman High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy J Clin Oncol 27 2009 2151 2156
22. G.H. Jackson Renal safety of ibandronate Oncologist 10 2005 14 18
23. M.A. Perazella, and G.S. Markowitz Bisphosphonate nephrotoxicity Kidney Int 74 2008 1385 1393
24. C.A. Migliorati, M.A. Siegel, and L.S. Elting Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment Lancet Oncol 7 2006 508 514
25. A. Badros, D. Weikel, and A. Salama, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors J Clin Oncol 24 2006 945 952
26. A. Bamias, E. Kastritis, and C. Bamia, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 2005 8580 8587
27. P.N. Sambrook Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw Nat Clin Pract Rheumatol 5 2009 6 7
28. A.O. Hoff, B.B. Toth, and K. Altundag, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826 836
29. C.I. Ripamonti, M. Maniezzo, and T. Campa, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates The experience of the National Cancer Institute of Milan Ann Oncol 20 2009 137 145
30. R. Coleman, N. Bundred, and R. De Boer, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [abstract] Cancer Res (Meeting Abstracts) 69 2009 4082
31. A.M. Brufsky, L.D. Bosserman, and R.R. Caradonna, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 2009 77 85
32. R.E. Coleman, M.C. Winter, and D. Cameron, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 2010 1099 1105
33. R. Aft, M. Naughton, and K. Trinkaus, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 2010 421 428
34. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. Epub 2010 April 1. Available from: www.springerlink.com.
35. K. Zarogoulidis, E. Boutsikou, and P. Zarogoulidis, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis Int J Cancer 125 2009 1705 1709
36. P.J. Bekker, D.L. Holloway, and A.S. Rasmussen, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 2004 1059 1066
37. S.R. Cummings, J. San Martin, and M.R. McClung, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
38. G.K. Ellis, H.G. Bone, and R. Chlebowski, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 2008 4875 4882
39. H.G. Bone, M.A. Bolognese, and C.K. Yuen, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2008 2149 2157
40. M.R. Smith, B. Egerdie, and N. Hernandez Toriz, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
41. D.V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects J Am Coll Cardiol 47 2006 1850 1857
42. P. Collin-Osdoby Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin Circ Res 95 2004 1046 1057
43. A.D. Anastasilakis, K.A. Toulis, and D.G. Goulis, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis Horm Metab Res 41 2009 721 729
44. Y.Y. Kong, H. Yoshida, and I. Sarosi, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
45. H. Park, O.J. Park, J. Shin, and Y. Choi Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cells Exp Mol Med 37 2005 524 532
46. B.R. Wong, R. Josien, and S.Y. Lee, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor J Exp Med 186 1997 2075 2080
47. Amgen Inc. Amgen press release. Denosumab demonstrated superiority over zometa in pivotal phase 3 head-to-head trial in prostate cancer patients with bone metastases. Published February 8, 2010. Available from: www.ext.amgen.com/media/media-pr-detail.jsp?year=2010&releaseID=1385163.
48. B.J. Edwards, M. Gounder, and J.M. McKoy, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw Lancet Oncol 9 2008 1166 1172
49. D. Santini, F. Martini, and M.E. Fratto, et al. In vivo effects of zoledronic acid on peripheral γσ T lymphocytes in early breast cancer patients Cancer Immunol Immunother 58 2009 31 38
50. D. Santini, B. Vincenzi, and R.A. Hannon, et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours Oncol Rep 15 2006 1351 1357
51. B. Vincenzi, D. Santini, and G. Dicuonzo, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients J Interferon Cytokine Res 25 2005 144 151